iBio is a preclinical-stage biotechnology company that develops precision antibody therapeutics for obesity and cardiometabolic diseases using an integrated AI drug discovery platform. The company leverages proprietary machine learning tools—including its Epitope Steering Engine for targeting functional hotspots on disease targets and generative AI for antibody optimization—to discover and advance novel biologic candidates that address limitations of existing treatments. iBio's lead programs target myostatin, Activin E, and other validated cardiometabolic pathways, with plans to initiate human clinical trials in the near term, while also pursuing partnerships that generate upfront and milestone payments and licensing its AI technology platform to other therapeutic areas.